Viking Therapeutics, Inc. (VKTX)
28.51
+0.78
(+2.81%)
USD |
NASDAQ |
Oct 09, 16:00
28.55
+0.04
(+0.14%)
After-Hours: 05:32
Viking Therapeutics Free Cash Flow : -418.44M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -418.44M |
| March 31, 2026 | -340.33M |
| December 31, 2025 | -278.68M |
| September 30, 2025 | -224.58M |
| June 30, 2025 | -152.54M |
| March 31, 2025 | -133.99M |
| December 31, 2024 | -87.79M |
| September 30, 2024 | -74.25M |
| June 30, 2024 | -71.94M |
| March 31, 2024 | -54.87M |
| December 31, 2023 | -73.38M |
| September 30, 2023 | -66.66M |
| June 30, 2023 | -60.50M |
| March 31, 2023 | -62.51M |
| December 31, 2022 | -48.40M |
| September 30, 2022 | -49.82M |
| June 30, 2022 | -47.25M |
| March 31, 2022 | -47.24M |
| December 31, 2021 | -47.59M |
| September 30, 2021 | -40.72M |
| June 30, 2021 | -35.12M |
| March 31, 2021 | -28.35M |
| Date | Value |
|---|---|
| December 31, 2020 | -21.78M |
| September 30, 2020 | -28.03M |
| June 30, 2020 | -26.11M |
| March 31, 2020 | -25.90M |
| December 31, 2019 | -24.75M |
| September 30, 2019 | -15.69M |
| June 30, 2019 | -17.79M |
| March 31, 2019 | -16.60M |
| December 31, 2018 | -18.76M |
| September 30, 2018 | -20.02M |
| June 30, 2018 | -17.85M |
| March 31, 2018 | -16.78M |
| December 31, 2017 | -14.76M |
| September 30, 2017 | -13.27M |
| June 30, 2017 | -12.60M |
| March 31, 2017 | -11.62M |
| December 31, 2016 | -11.07M |
| September 30, 2016 | -11.91M |
| June 30, 2016 | -12.65M |
| March 31, 2016 | -11.05M |
| December 31, 2015 | -8.732M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Eli Lilly & Co. | 13.56B |
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| Amgen, Inc. | 10.18B |
| Vertex Pharmaceuticals, Inc. | 3.796B |
| Ironwood Pharmaceuticals, Inc. | 185.55M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -125.17M |
| Cash from Investing (Quarterly) | 109.43M |
| Cash from Financing (Quarterly) | 23.59M |
| Free Cash Flow Per Share (Quarterly) | -1.077 |
| Free Cash Flow to Equity (Quarterly) | -129.26M |
| Free Cash Flow to Firm (Quarterly) | -125.17M |
| Free Cash Flow Yield | -12.81% |